GSK licenses Shigella vaccine candidate to Bharat Biotech

GSK (GSK) announced that it has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited, BBIL. The agreement paves the way for the ongoing development and potential distribution of the vaccine in low- and middle-income countries where Shigella, the leading bacterial cause of diarrhoea, poses a significant health threat to children under five. Thomas Breuer, Chief Global Health Officer, GSK said: “With young children in lower-income countries disproportionately impacted by Shigella, the development of a low-cost vaccine is an important goal for global public health. With no licensed vaccines widely available, the development of our Shigella vaccine candidate which has demonstrated promising clinical trial results, fills us with immense pride.”